Phase 2 N=31 Lapatinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Percentage of Patients With Progression-free Survival > 6 Months — 10 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=35 RAD001 in Recurrent Endometrial Cancer Patients
Endometrial Cancer
Primary: Number of Participants With Objective Response Plus Stable Disease Rate (CR + PR + SD) — 0; 0; 14; 17 participants
Phase 2 N=34 Sunitinib Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Endometrioid Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Objective Response Rate — 6; 6; 16; 5 Participants
Phase 2 N=53 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Incidence of Adverse Effects as Assessed by the National Cancer Institute CTCAE v. 4.0 — 0; 0; 0; 3 Participants
Phase 2 N=24 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Proportion of Patients With Objective Tumor Response Rate (Complete Response [CR] or Partial Response [PR]) Using RECIST Version 1.0 — 1; 0 Participants
Phase 2 N=56 Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Progression-free Survival Greater Than 6 Months — 31; 21 participants
Phase 2 N=28 Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer
Endometrial Cancer · Recurrent Endometrial Cancer
Primary: Clinical Benefit Rate (CBR) — 7; 18 Participants
Phase 2 N=28 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Response — 0 percentage of participants
Phase 2 N=37 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mucinous Adenocarcinoma
Primary: Number of Participants With Adverse Events — 1; 1; 2; 4 Participants
Phase 2 N=54 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Number of Participants With or Without Progression-free Survival for > 6 Months by Response Evaluation Criteria for Solid Tumors (RECIST) — 39; 11 participants
Phase 2 N=11 Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Endometrioid Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma · Endometrial Serous Adenocarcinoma
Primary: Frequency of Objective Response Defined by RECIST 1.1 Criteria — 0.0 percentage of participants
Phase 2 N=33 Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Overall Disease Control Rate — 17 percentage of participants
Phase 2 N=45 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 30.2 percentage of participants
Phase 2 N=27 A Trial for Patients With Advanced/Recurrent Endometrial Cancer
Neoplasms · Neoplasms by Site · Urogenital Neoplasms
Primary: Tumor Response — 0; 1; 12; 11 participants
Phase 3 N=1,381 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
Recurrent Uterine Corpus Carcinoma · Stage IIIA Uterine Corpus Cancer AJCC v7 · Stage IIIB Uterine Corpus Cancer AJCC v7
Primary: Number of Participants Alive at Time of Last Follow-up. — 376; 385; 271; 280 Participants
Phase 2 N=52 Ixabepilone in Treating Patients With Recurrent or Persistent Endometrial Cancer
Endometrial Adenocarcinoma · Recurrent Endometrial Carcinoma · Stage IV Endometrial Carcinoma
Primary: Tumor Response — 12 percentage of participants
Phase 2 N=79 Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
Metastatic Endometrial Cancer
Primary: Progression Free Survival (PFS) — 28.1; 8.7 months
Phase 2 N=35 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma
Primary: Progression-free Survival > 6 Months — 18.8 percentage of participants
Phase 2 N=21 Gemcitabine and Cisplatin for Advanced or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Participant Responses — 2; 8; 4; 6 participants
Phase 2 N=102 Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
Endometrial Adenosquamous Carcinoma · Endometrial Clear Cell Adenocarcinoma · Endometrial Mixed Cell Adenocarcinoma
Primary: Response Rate — 9; 2 Participants
Phase 2 N=49 VEGF Trap in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: 6 Month Progression-free Survival — 18 participants
Phase 2 N=37 Intravenous Weekly Topotecan In Subjects With Recurrent Or Persistent Endometrial Cancer
Neoplasms, Endometrial · Endometrial Cancer
Primary: Best Overall Response — 0; 1; 9; 23 Participants
Phase 2 N=41 Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer
Endometrial Cancer
Primary: Percent of Patients Estimated to be Progression-Free and Alive — 86; 76; 68 Percentage of Patients
Phase 2 N=35 Fulvestrant for the Treatment of Recurrent or Metastatic Endometrial Carcinoma.
Endometrial Carcinoma
Primary: Determination (for ITT (Intet-to-Treat Set): Efficacy of a Monthly Administration of Fulvestrant in Patients With Recurrent or Metastatic Endometrial Carcinoma by…
Phase 2 N=53 Bevacizumab and Temsirolimus in Treating Patients With Recurrent or Persistent Endometrial Cancer
Recurrent Endometrial Carcinoma
Primary: Tumor Response — 24.5 percentage of participants
Phase 2 N=50 Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer
Recurrent Endometrial Endometrioid Adenocarcinoma · Recurrent Uterine Corpus Carcinoma · Stage III Uterine Corpus Cancer AJCC v7
Primary: Clinical Activity of Combination Enzalutamide, Carboplatin and Paclitaxel Represented as Objective Tumor Response (Complete Response (CR) + Partial Response (PR)). — 68…
Phase 2 N=46 Pembro/Carbo/Taxol in Endometrial Cancer
Endometrial Cancer · Endometrial Adenocarcinoma
Primary: Objective Response Rates (ORR) — 74.4 percentage of participants
Phase 2 N=62 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer
Endometrial Adenocarcinoma · Endometrial Adenosquamous Cell Carcinoma · Endometrial Clear Cell Carcinoma
Primary: Objective Clinical Response Rate — 13.8; 4.0 percentage of patients with response
N/A N=43 Letrozole as a Treatment of Endometrial Cancer
Endometrial Carcinoma
Primary: Changes in Ki67 Expression After About 3 Weeks of Letrozole Treatment for Patients With Endometrial Cancer — -3.75; 1.583 percentage of Ki67 staining cells — p=0.0373
Phase 2 N=30 Papillary Serous Carcinoma of the Endometrium
Endometrial Cancer
Primary: Overall Survival at 2 Years and 5 Years — 93; 85 percentage of participants